1. Home
  2. EIX vs UTHR Comparison

EIX vs UTHR Comparison

Compare EIX & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Edison International

EIX

Edison International

HOLD

Current Price

$71.59

Market Cap

28.4B

Sector

Utilities

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$513.12

Market Cap

23.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EIX
UTHR
Founded
1886
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.4B
23.1B
IPO Year
1994
1999

Fundamental Metrics

Financial Performance
Metric
EIX
UTHR
Price
$71.59
$513.12
Analyst Decision
Hold
Buy
Analyst Count
13
14
Target Price
$72.09
$567.57
AVG Volume (30 Days)
3.3M
430.2K
Earning Date
04-28-2026
05-06-2026
Dividend Yield
5.17%
N/A
EPS Growth
248.94
13.07
EPS
1.37
13.07
Revenue
$19,317,000,000.00
$1,483,300,000.00
Revenue This Year
N/A
$6.39
Revenue Next Year
$3.17
$14.18
P/E Ratio
$54.50
$39.86
Revenue Growth
9.76
2.38
52 Week Low
$52.00
$302.19
52 Week High
$81.62
$609.35

Technical Indicators

Market Signals
Indicator
EIX
UTHR
Relative Strength Index (RSI) 45.54 46.98
Support Level $69.35 $464.92
Resistance Level $72.89 $546.08
Average True Range (ATR) 2.20 15.66
MACD 0.31 1.22
Stochastic Oscillator 51.82 55.40

Price Performance

Historical Comparison
EIX
UTHR

About EIX Edison International

Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: